Reduction of tumor growth was observed in either AUY-922 or anti-CTLA monotherapy, but a further decrease of tumor growth was observed in the AUY-922 and anti-CTLA4 combinational treatment group (Supplementary Fig. 9B–D). This evidence concerns the gene CTLA4 and neoplasm.